Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Declining mortality rates in children admitted to ICU following HCT

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Correction: ABO incompatibile graft management in pediatric transplantation

    Research output: Contribution to journalComment/debateResearchpeer-review

  • Adriana Balduzzi
  • Jean-Hugues Dalle
  • Jacek Wachowiak
  • Isaac Yaniv
  • Akif Yesilipek
  • Petr Sedlacek
  • Marc Bierings
  • Marianne Ifversen
  • Sabina Sufliarska
  • Krzysztof Kalwak
  • Arjan Lankester
  • Jacek Toporski
  • Lucia Di Maio
  • Evgenia Glogova
  • Ulrike Poetschger
  • Christina Peters
View graph of relations

Eligibility criteria for hematopoietic stem cell transplantation (HSCT) in acute lymphoblastic leukemia (ALL) vary according to disease characteristics, response to treatment, and type of available donor. As the risk profile of the patient worsens, a wider degree of HLA mismatching is considered acceptable. A total of 138 children and adolescents who underwent HSCT from HLA-identical sibling donors (MSDs) and 210 who underwent HSCT from matched donors (MDs) (median age, 9 years; 68% male) in 10 countries were enrolled in the International-BFM ALL SCT 2007 prospective study to assess the impact of donor type in HSCT for pediatric ALL. The 4-year event-free survival (65 ± 5% vs 61 ± 4%; P = .287), overall survival (72 ± 4% versus 68 ± 4%; P = .235), cumulative incidence of relapse (24 ± 4% versus 25 ± 3%; P = .658) and nonrelapse mortality (10 ± 3% versus 14 ± 3%; P = .212) were not significantly different between MSD and MD graft recipients. The risk of extensive chronic (cGVHD) was lower in MD graft recipients than in MSD graft recipients (hazard ratio [HR], .38; P = .002), and the risks of severe acute GVHD (aGVHD) and cGVHD were higher in peripheral blood stem cell graft recipients than in bone marrow graft recipients (HR, 2.06; P = .026). Compared with the absence of aGVHD, grade I-II aGVHD was associated with a lower risk of graft failure (HR, .63; P = .042) and grade III-IV aGVHD was associated with a higher risk of graft failure (HR, 1.85; P = .020) and nonleukemic death (HR, 8.76; P < .0001), despite a lower risk of relapse (HR, .32; P = .021). Compared with the absence of cGVHD, extensive cGVHD was associated with a higher risk of nonleukemic death (HR, 8.12; P < .0001). Because the outcomes of transplantation from a matched donor were not inferior to those of transplantation from an HLA-identical sibling, eligibility criteria for transplantation might be reviewed in pediatric ALL and possibly in other malignancies as well. Bone marrow should be the preferred stem cell source, and the addition of MTX should be considered in MSD graft recipients.

Original languageEnglish
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Issue number11
Pages (from-to)2197-2210
Number of pages14
Publication statusPublished - 2019

ID: 58993885